DIVAA™isthefirstinvivosystemforthestudyofangiogenesisthatprovidesquantitativeandreproducIBLeresults.Duringthecourseoftheassay,implantgradesiliconecylindersclosedatoneend,calledangioreactors,arefilledwith20μlofTrevigen’sPathClear®basementmembraneextract(BME)premixedwithorwithoutangiogenic-modulatingfactors*.Theseangioreactorsarethenimplantedsubcutaneouslyinthedorsalflankofnudemice.Accompaniedwiththeonsetofangiogenesis,vascularendothelialcellsproceedtogrowintotheBMEandformvesselsintheangioreactor.Asearlyasninedayspost-implantation,thereareenoughcellstodetermineaneffectivedoseresponsetoangiogenicmodulatingfactors.Thesleekdesignoftheangioreactorprovidesastandardizedplatformforreproducibleandquantifiableinvivoangiogenesisassays.Comparedtotheplugassay,theangioreactorpreventsassayerrorsduetoabsorptionofthebasementmembraneextractbythemouse.Inaddition,theangioreactorusesonlyafractionofthematerialsconservingbothBMEandtestcompoundsused,anduptofourangioreactorsmaybeimplantedineachmouse,allowingforgreaterstatisticalpower.Trevigen’sDIVAAhasbeenusedinavarietyofinvestigations.
*ThePathClear®designationmeans:
Catalog#3450-048-Kincludes: | ||
CatalogNumber | Description | Qty |
3450-048-02 | DIVAABME | 1 |
3450-048-04 | DIVAAFGF-2PositiveControl | 1 |
3450-048-05 | DIVAACellSperse | 1 |
3450-048-B9 | DIVAAFGF-2(300ng)/VEGF(100ng) | 1 |
3450-048-01 | DIVAAAngioreactor | 1 |
3450-048-03 | DIVAAWashBuffer | 1 |
3450-048-06 | DIVAAFITC-Lectin200X | 1 |
3450-048-07 | 25XFITC-LectinDiluent | 1 |
3450-048-08 | HeparinSolution | 1 |
Trevigen提供多种产品来测量氧化应激和DNA损伤。我们的彗星实验®产品线是为彗星试验,其中包括试剂,试剂盒,设备和分析软件的唯一完整和优化的商用平台。我们的TACS ®(Trevigen公司凋亡的细胞系统)产品已被广泛使用,并列举多年来,研究人员对他们的无与伦比的品质认可。